Unlock stock picks and a broker-level newsfeed that powers Wall Street.

OTC Markets OTCPK - Delayed Quote USD

GALDERMA GROUP AG (GDERF)

Compare
108.10
0.00
(0.00%)
As of April 15 at 4:00:00 PM EDT. Market Open.
All All Favorites Text Statistics Technicals Fibonacci Markings Lines
Loading Chart for GDERF

Recent News: GDERF

View More
Galderma Launches Sculptra® in China, Further Fueling Its Growth Into One of the Fastest Growing Aesthetics Markets

Galderma Launches Sculptra® in China, Further Fueling Its Growth Into One of the Fastest Growing Aesthetics Markets
Business Wire yesterday
AMWC 2025: Galderma Pushes the Innovation Frontier With Updates From Its Unparalleled Portfolio Designed to Meet the Needs of the Aesthetic Community

AMWC 2025: Galderma Pushes the Innovation Frontier With Updates From Its Unparalleled Portfolio Designed to Meet the Needs of the Aesthetic Community
Business Wire 27 days ago
Galderma's Differin is helping destigmatize acne care with first in category Roblox experience

Galderma's Differin is helping destigmatize acne care with first in category Roblox experience
PR Newswire 30 days ago

Galderma Group AG (XSWX:GALD) Full Year 2024 Earnings Call Highlights: Record Sales and ...
GuruFocus.com last month
Galderma Shares Slide on Expected Hit From Investments

Galderma Shares Slide on Expected Hit From Investments
The Wall Street Journal last month
Galderma to discuss U.S. tariffs with retailers, sees "moving target"

Galderma to discuss U.S. tariffs with retailers, sees "moving target"
Reuters last month
Galderma Delivers 2024 Record Net Sales of 4.410 Billion USD, up 9.3% Year-on-Year at Constant Currency1, and Record Core EBITDA of 1.031 Billion USD, While Preparing to Accelerate Its Growth Trajectory Into 2025 and Beyond

Galderma Delivers 2024 Record Net Sales of 4.410 Billion USD, up 9.3% Year-on-Year at Constant Currency1, and Record Core EBITDA of 1.031 Billion USD, While Preparing to Accelerate Its Growth Trajectory Into 2025 and Beyond
Business Wire last month
AAD 2025: Galderma to Present Extensive Updates From Across Its Dermatology Portfolio, Demonstrating Its Category Leadership and Strong Momentum

AAD 2025: Galderma to Present Extensive Updates From Across Its Dermatology Portfolio, Demonstrating Its Category Leadership and Strong Momentum
Business Wire last month
Galderma’s Nemluvio® (Nemolizumab) Granted Marketing Authorization in the United Kingdom and Switzerland for Moderate-to-Severe Atopic Dermatitis and Prurigo Nodularis

Galderma’s Nemluvio® (Nemolizumab) Granted Marketing Authorization in the United Kingdom and Switzerland for Moderate-to-Severe Atopic Dermatitis and Prurigo Nodularis
Business Wire last month
Galderma’s Nemluvio® (Nemolizumab) Approved in the European Union for Moderate-to-Severe Atopic Dermatitis and Prurigo Nodularis

Galderma’s Nemluvio® (Nemolizumab) Approved in the European Union for Moderate-to-Severe Atopic Dermatitis and Prurigo Nodularis
Business Wire last month
IMCAS 2025: New Galderma Phase IIIb Data Reinforce Rapid Onset and Long-lasting Aesthetic Improvement with RelabotulinumtoxinA (Relfydess™)

IMCAS 2025: New Galderma Phase IIIb Data Reinforce Rapid Onset and Long-lasting Aesthetic Improvement with RelabotulinumtoxinA (Relfydess™)
Business Wire 2 months ago
View More
Waiting for permission
Allow microphone access to enable voice search

Try again.